Falcon Point Capital LLC raised its position in shares of Vascular Solutions Inc. (NASDAQ:VASC) by 12.4% during the second quarter, Holdings Channel reports. The firm owned 42,579 shares of the medical device company’s stock after buying an additional 4,710 shares during the period. Falcon Point Capital LLC’s holdings in Vascular Solutions were worth $1,774,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Envestnet Asset Management Inc. increased its stake in shares of Vascular Solutions by 11.6% in the first quarter. Envestnet Asset Management Inc. now owns 6,036 shares of the medical device company’s stock worth $196,000 after buying an additional 628 shares in the last quarter. Bank of Montreal Can acquired a new stake in Vascular Solutions during the second quarter valued at $202,000. BNP Paribas Arbitrage SA increased its stake in Vascular Solutions by 52.2% in the second quarter. BNP Paribas Arbitrage SA now owns 6,772 shares of the medical device company’s stock valued at $282,000 after buying an additional 2,324 shares during the period. Arizona State Retirement System increased its stake in Vascular Solutions by 4.7% in the first quarter. Arizona State Retirement System now owns 8,850 shares of the medical device company’s stock valued at $288,000 after buying an additional 400 shares during the period. Finally, Menta Capital LLC acquired a new stake in Vascular Solutions during the first quarter valued at $320,000. 82.08% of the stock is owned by hedge funds and other institutional investors.
Vascular Solutions Inc. (NASDAQ:VASC) traded down 1.39% during mid-day trading on Friday, hitting $49.56. The company had a trading volume of 84,075 shares. The company has a 50-day moving average price of $48.18 and a 200 day moving average price of $40.36. The company has a market capitalization of $866.85 million, a P/E ratio of 91.78 and a beta of 0.58. Vascular Solutions Inc. has a 52-week low of $24.34 and a 52-week high of $50.72.
Vascular Solutions (NASDAQ:VASC) last issued its quarterly earnings results on Monday, July 25th. The medical device company reported $0.33 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.30 by $0.03. Vascular Solutions had a return on equity of 16.32% and a net margin of 6.22%. The firm earned $41.20 million during the quarter, compared to analysts’ expectations of $41.40 million. During the same period in the previous year, the business earned $0.29 earnings per share. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. On average, analysts forecast that Vascular Solutions Inc. will post $1.24 EPS for the current fiscal year.
Several analysts have recently weighed in on VASC shares. Sidoti downgraded Vascular Solutions from a “buy” rating to a “neutral” rating and set a $47.00 target price for the company. in a research report on Tuesday, July 12th. Canaccord Genuity reiterated a “buy” rating on shares of Vascular Solutions in a research report on Wednesday, August 10th. Zacks Investment Research upgraded Vascular Solutions from a “hold” rating to a “buy” rating and set a $52.00 target price for the company in a research report on Thursday, July 28th. TheStreet upgraded Vascular Solutions from a “hold” rating to a “buy” rating in a research report on Monday, July 25th. Finally, Piper Jaffray Cos. lifted their target price on Vascular Solutions from $45.00 to $49.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 26th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $47.38.
In other Vascular Solutions news, CEO Howard Root sold 40,000 shares of the company’s stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $45.11, for a total value of $1,804,400.00. Following the completion of the sale, the chief executive officer now directly owns 347,840 shares in the company, valued at approximately $15,691,062.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP William Rutstein sold 10,011 shares of the company’s stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $46.26, for a total value of $463,108.86. The disclosure for this sale can be found here. Corporate insiders own 6.90% of the company’s stock.
About Vascular Solutions
Vascular Solutions, Inc is a medical device company focused on bringing clinically advanced solutions to the market for treating coronary and peripheral vascular disease. The Company’s product line consists of devices and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists and vein practices around the world.
Want to see what other hedge funds are holding VASC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vascular Solutions Inc. (NASDAQ:VASC).
Receive News & Ratings for Vascular Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.